The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Factors Influencing the Magnitude and Clinical Significance of Drug Interactions Between Azole Antifungals and Select Immunosuppressants
Open accessAbstract
The magnitude of drug interactions between azole antifungals and immunosuppressants is drug and patient specific and depends on the potency of the azole inhibitor involved, the resulting plasma concentrations of each drug, the drug formulation, and interpatient variability. Many factors contribute to variability in the magnitude and clinical significance of drug interactions between an immunosuppressant such as cyclosporine, tacrolimus, or sirolimus and an antifungal agent such as ketoconazole, fluconazole, itraconazole, voriconazole, or posaconazole. By bringing similarities and differences among these agents and their potential interactions to clinicians' attention, they can appreciate and apply these findings in a individualized patient approach rather than follow only the one‐size‐fits‐all dosing recommendations suggested in many tertiary references. Differences in metabolism and in the inhibitory potency of cytochrome P450 3A4 and P‐glycoprotein influence the onset, magnitude, and resolution of drug interactions and their potential effect on clinical outcomes. Important issues are the route of administration and the decision to preemptively adjust dosages versus intensive monitoring with subsequent dosage adjustments. We provide recommendations for the concomitant use of these agents, including suggestions regarding contraindicated combinations, those best avoided, and those requiring close monitoring of drug dosages and plasma concentrations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aspergillosis Case-Fatality Rate: Systematic Review of the Literature
Lin, S.-J., Schranz, J., & Teutsch, S. M. (2001) · Clinical Infectious Diseases · doi:10.1086/318483 · Cited by 1,409
Dresser, G. K., Spence, J. D., & Bailey, D. G. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200038010-00003 · Cited by 908
IN VITRO AND IN VIVO DRUG INTERACTIONS INVOLVING HUMAN CYP3A
Thummel, K. E., & Wilkinson, G. R. (1998) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.38.1.389 · Cited by 831
Inhibition and Induction of Cytochrome P450 and the Clinical Implications
Lin, J. H., & Lu, A. Y. H. (1998) · Clinical Pharmacokinetics · doi:10.2165/00003088-199835050-00003 · Cited by 829
Voriconazole: A New Triazole Antifungal Agent
Johnson, L. B., & Kauffman, C. A. (2003) · Clinical Infectious Diseases · doi:10.1086/367933 · Cited by 785
Bertz, R. J., & Granneman, G. R. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199732030-00004 · Cited by 755
Trends in Mortality Due to Invasive Mycotic Diseases in the United States, 1980–1997
McNeil, M. M., Nash, S. L., Hajjeh, R. A., Phelan, M. A., Conn, L. A., Plikaytis, B. D., & Warnock, D. W. (2001) · Clinical Infectious Diseases · doi:10.1086/322606 · Cited by 657
The Gut as a Barrier to Drug Absorption: Combined Role of Cytochrome P450 3A and P-Glycoprotein
Zhang, Y., & Benet, L. Z. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140030-00002 · Cited by 518
Effects of the Antifungal Agents on Oxidative Drug Metabolism: Clinical Relevance
Venkatakrishnan, K., von Moltke, L. L., & Greenblatt, D. J. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200038020-00002 · Cited by 508
Clinical Pharmacokinetics of Everolimus
Kirchner, G. I., Meier-Wiedenbach, I., & Manns, M. P. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443020-00002 · Cited by 508
History of the development of azole derivatives
Maertens, J. A. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1470-9465.2004.00841.x · Cited by 475
Mechanisms of Clinically Relevant Drug Interactions Associated with Tacrolimus
Christians, U., Jacobsen, W., Benet, L. Z., & Lampen, A. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241110-00003 · Cited by 323
Human Drug Metabolism and the Cytochromes P450: Application and Relevance of In Vitro Models
Venkatakrishnan, K., von Moltke, L. L., & Greenblatt, D. J. (2001) · The Journal of Clinical Pharmacology · doi:10.1177/00912700122012724 · Cited by 308
Clinical Pharmacokinetics of Sirolimus
Mahalati, K., & Kahan, B. D. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140080-00002 · Cited by 302
The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine*
Gomez, D. Y., Wacher, V. J., Tomlanovich, S. J., Hebert, M. F., & Benet, L. Z. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90067-5 · Cited by 282
Systemic Antifungal Agents: Drug Interactions of Clinical Significance
Albengres Herv??, E., Lou??, L., & Tillement, J.-P. (1998) · Drug Safety · doi:10.2165/00002018-199818020-00001 · Cited by 280
ROLE OF ITRACONAZOLE METABOLITES IN CYP3A4 INHIBITION
Isoherranen, N., Kunze, K. L., Allen, K. E., Nelson, W. L., & Thummel, K. E. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.000315 · Cited by 276
Dunn, C. J., Wagstaff, A. J., Perry, C. M., Plosker, G. L., & Goa, K. L. (2001) · Drugs · doi:10.2165/00003495-200161130-00006 · Cited by 276
Tacrolimus oral bioavailability doubles with coadministration of ketoconazole*
Floren, L. C., Bekersky, I., Benet, L. Z., Mekki, Q., Dressler, D., Lee, J. W., Roberts, J. P., & Hebert, M. F. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90150-8 · Cited by 268
Gibbs, M. A., Thummel, K. E., Shen, D. D., & Kunze, K. L. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15274-9 · Cited by 245
Molecular and physical mechanisms of first-pass extraction.
Hall, S. D., Thummel, K. E., Watkins, P. B., Lown, K. S., Benet, L. Z., Paine, M. F., Mayo, R. R., Turgeon, D. K., Bailey, D. G., Fontana, R. J., et al. (1999) · PubMed · Cited by 235
Interaction of Common Azole Antifungals with P Glycoprotein
Wang, E.-J., Lew, K., Casciano, C. N., Clement, R. P., & Johnson, W. W. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.1.160-165.2002 · Cited by 233
Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study
Wexler, D., Courtney, R., Richards, W., Banfield, C., Lim, J., & Laughlin, M. (2004) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2004.01.005 · Cited by 199
Benet, L., Cummins, C., & Wu, C. (2003) · Current Drug Metabolism · doi:10.2174/1389200033489389 · Cited by 188
Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients
Romero, A. J., Pogamp, P. L., Nilsson, L., & Wood, N. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.121911 · Cited by 169
Venkataramanan, R., Zang, S., Gayowski, T., & Singh, N. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.9.3091-3093.2002 · Cited by 152
Voriconazole: A New Triazole Antifungal Agent
Pearson, M., Rogers, P. D., Cleary, J. D., & Chapman, S. W. (2003) · Annals of Pharmacotherapy · doi:10.1345/aph.1c261 · Cited by 148
Pharmacokinetic Drug Interactions with Antimicrobial Agents
Gillum, J. G., Israel, D. S., & Polk, R. E. (1993) · Clinical Pharmacokinetics · doi:10.2165/00003088-199325060-00005 · Cited by 143
P‐glycoprotein and Drug Therapy in Organ Transplantation
Lo, A., & Burckart, G. J. (1999) · The Journal of Clinical Pharmacology · doi:10.1177/00912709922011755 · Cited by 125
Voriconazole and Sirolimus Coadministration after Allogeneic Hematopoietic Stem Cell Transplantation
Marty, F. M., Lowry, C. M., Cutler, C. S., Campbell, B., Fiumara, K., Baden, L. R., & Antin, J. H. (2006) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2005.12.032 · Cited by 112
Symposium Article: Molecular and Physical Mechanisms of First-Pass Extraction
Hall, S. D., Thummel, K. E., Watkins, P. B., Lown, K. S., Benet, L. Z., Paine, M. F., Mayo, R. R., Turgeon, D. K., Bailey, D. G., Fontana, R. J., et al. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15271-3 · Cited by 109
Bachmann, K. A., & Lewis, J. D. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1e508 · Cited by 108
Systemic mycoses in the immunocompromised host: an update in antifungal therapy
Kontoyiannis, D. P., Mantadakis, E., & Samonis, G. (2003) · Journal of Hospital Infection · doi:10.1053/jhin.2002.1278 · Cited by 104
INTERACTION BETWEEN CYCLOSPORINE AND FLUCONAZOLE IN RENAL ALLOGRAFT RECIPIENTS
Canafax, D. M., Graves, N. M., Hilligoss, D. M., Carleton, B., Gardner, M., & Matas, A. J. (1991) · Transplantation · doi:10.1097/00007890-199105000-00016 · Cited by 103
FLUCONAZOLE THERAPY IN TRANSPLANT RECIPIENTS RECEIVING FK506
Mañez, R., Martin, M., Raman, D., Silverman, D., Jain, A., Warty, V., Gonzalez-Pinto, I., Kusne, S., & Starzl, T. E. (1994) · Transplantation · doi:10.1097/00007890-199405270-00022 · Cited by 99
Osowski, C. L., Dix, S. P., Lin, L. S., Mullins, R. E., Geller, R. B., & Wingard, J. R. (1996) · Transplantation · doi:10.1097/00007890-199604270-00026 · Cited by 95
Drug interactions of the newer oral antifungal agents
Katz (1999) · British Journal of Dermatology · doi:10.1046/j.1365-2133.1999.00011.x · Cited by 95
Active Drug Transport of Immunosuppressants: New Insights for Pharmacokinetics and Pharmacodynamics
Christians, U., Strom, T., Zhang, Y. L., Steudel, W., Schmitz, V., Trump, S., & Haschke, M. (2006) · Therapeutic Drug Monitoring · doi:10.1097/01.ftd.0000183385.27394.e7 · Cited by 88
McConn, D. J., Lin, Y. S., Allen, K. E., Kunze, K. L., & Thummel, K. E. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.10.1083 · Cited by 85
Reversible adrenal insufficiency induced by ketoconazole.
Tucker, W. S., Snell, B. B., Island, D. P., & Gregg, C. R. (1985) · PubMed · Cited by 83
Update on Drug Interactions with Azole Antifungal Agents
Lomaestro, B. M., & Piatek, M. A. (1998) · Annals of Pharmacotherapy · doi:10.1345/aph.17271 · Cited by 70
Induction of Fluconazole Metabolism by Rifampin: In Vivo Study in Humans
Apseloff, G., Hilligoss, D. M., Gardner, M., Henry, E. B., Inskeep, P. B., Gerber, N., & Lazar, J. D. (1991) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1991.tb03718.x · Cited by 69
Drug–drug interactions of antifungal agents and implications for patient care
Gubbins, P. O., & Amsden, J. R. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.13.2231 · Cited by 66
Rubin, R. H., Ikonen, T. S., Gummert, J. F., & Morris, R. E. (1999) · Transplant Infectious Disease · doi:10.1034/j.1399-3062.1999.10104.x · Cited by 61
Does differing metabolism by cytochrome P450 have clinical importance?
Davidson, M. H. (2000) · Current Atherosclerosis Reports · doi:10.1007/s11883-000-0090-4 · Cited by 54
Billaud, E. M., Guillemain, R., Tacco, F. M. D. S., & Chevalier, P. G. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.00784.x · Cited by 42
The Clinical and Economic Potential of Cyclosporin Drug Interactions
Martin, J. E., DAOUD, A., Schroeder, T., & Royfirst, M. (1999) · PharmacoEconomics · doi:10.2165/00019053-199915040-00001 · Cited by 41
Clinical impact of drug-drug interactions with systemic azole antifungals
Bates, D. W., & Yu, D. (2003) · Drugs of today · doi:10.1358/dot.2003.39.10.799473 · Cited by 40
Csako, G., McGriff, N. J., Rotman-Pikielny, P., Sarlis, N. J., & Pucino, F. (2001) · Annals of Pharmacotherapy · doi:10.1345/aph.1a031 · Cited by 40
Effects of Itraconazole on Tacrolimus Blood Concentrations in a Renal Transplant Recipient
Capone, D., Gentile, A., Imperatore, P., Palmiero, G., & Basile, V. (1999) · Annals of Pharmacotherapy · doi:10.1345/aph.18409 · Cited by 39
Fluconazole-sirolimus drug interaction
Cervelli, M. J. (2002) · Transplantation · doi:10.1097/00007890-200211270-00024 · Cited by 38
REJECTION AND HEPATITIS IN LIVER TRANSPLANTS
Máñez, R., Demetris, A. J., & Starzl, T. E. (1994) · Transplantation · doi:10.1097/00007890-199457120-00027 · Cited by 37
Neal, J. M., Kunze, K. L., Levy, R. H., O’Reilly, R. A., & Trager, W. F. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.8.1043 · Cited by 33
Treatment of opportunistic mycoses: how long is long enough?
Singh, N. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00802-8 · Cited by 33
Ketoconazole and Fluconazole Inhibition of the Metabolism of Cyclosporin A by Human Liver In Vitro
Omar, G., Whiting, P. H., HAWKSWORTH, G. M., Humphrey, M., & Burke, M. D. (1997) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199708000-00013 · Cited by 31
Coadministration of itraconazole and tacrolimus after thoracic organ transplantation
Banerjee, R., Leaver, N., Lyster, H. S., & Banner, N. R. (2001) · Transplantation Proceedings · doi:10.1016/s0041-1345(00)02608-7 · Cited by 30
Overview: pathogenesis of fungal infections in the organ transplant recipient
Rubin, R. H. (2002) · Transplant Infectious Disease · doi:10.1034/j.1399-3062.4.s3.2.x · Cited by 27
El-Dahshan, K. F., Bakr, M. A., Donia, A. F., Badr, A. E.-S., & Sobh, M. A. K. (2004) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh191 · Cited by 18
Cited by
Galgiani, J. N., Ampel, N. M., Blair, J. E., Catanzaro, A., Geertsma, F., Hoover, S. E., Johnson, R. H., Kusne, S., Lisse, J., MacDonald, J. D., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw360 · Cited by 622
Pharmacokinetic/Pharmacodynamic Profile of Posaconazole
Li, Y., Theuretzbacher, U., Clancy, C. J., Nguyen, M. H., & Derendorf, H. (2010) · Clinical Pharmacokinetics · doi:10.2165/11319340-000000000-00000 · Cited by 450
Current Concepts in Antifungal Pharmacology
Lewis, R. E. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2011.0247 · Cited by 377
Husain, S., & Camargo, J. F. (2019) · Clinical Transplantation · doi:10.1111/ctr.13544 · Cited by 302
Micafungin breakthrough fungemia in patients with hematological disorders
Kimura, M., Araoka, H., Yamamoto, H., Nakamura, S., Nagi, M., Yamagoe, S., Miyazaki, Y., Ogura, S., Mitsuki, T., Yuasa, M., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02183-17 · Cited by 37
Metadata
- Authors
- Saad, A. H., DePestel, D. D., & Carver, P. L.
- Venue
- Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Publisher
- Wiley
- Published
- 2006-12
- Volume
- 26
- Issue
- 12
- Pages
- 1730-1744
- ISSN
- 0277-0008 (ISSN-L)
- 1875-9114
- OpenAlex
- W2118847922
- Cited by
- 295
- References
- 58
- FWCI
- 11.47
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.